SE0100472D0 - Nya metalloproteaser som har trombospondindomäner och nukleinsyrakompositioner som kodar för dessa - Google Patents

Nya metalloproteaser som har trombospondindomäner och nukleinsyrakompositioner som kodar för dessa

Info

Publication number
SE0100472D0
SE0100472D0 SE0100472A SE0100472A SE0100472D0 SE 0100472 D0 SE0100472 D0 SE 0100472D0 SE 0100472 A SE0100472 A SE 0100472A SE 0100472 A SE0100472 A SE 0100472A SE 0100472 D0 SE0100472 D0 SE 0100472D0
Authority
SE
Sweden
Prior art keywords
nucleic acid
acid compositions
applications
metalloproteases
thrombospondome
Prior art date
Application number
SE0100472A
Other languages
English (en)
Other versions
SE0100472L (sv
Inventor
Renu Anand Heller
Paul Klonowski
Fengrong Zuo
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SE0100472D0 publication Critical patent/SE0100472D0/sv
Publication of SE0100472L publication Critical patent/SE0100472L/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SE0100472A 2000-02-18 2001-02-14 Nya metalloproteaser som har trombospondindomäner och nukleinsyrakompositioner som kodar för dessa SE0100472L (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18415200P 2000-02-18 2000-02-18
FR0111527A FR2821085A1 (fr) 2000-02-18 2001-09-06 Nouvelles metalloproteases possedant des domaines thrombospondine et compositions d'acides nucleiques les codant

Publications (2)

Publication Number Publication Date
SE0100472D0 true SE0100472D0 (sv) 2001-02-14
SE0100472L SE0100472L (sv) 2001-08-19

Family

ID=26213171

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0100472A SE0100472L (sv) 2000-02-18 2001-02-14 Nya metalloproteaser som har trombospondindomäner och nukleinsyrakompositioner som kodar för dessa

Country Status (8)

Country Link
US (1) US20020107361A1 (sv)
JP (1) JP2001286289A (sv)
AU (1) AU2303301A (sv)
DE (1) DE10107360A1 (sv)
FR (2) FR2806738A1 (sv)
GB (1) GB2361702A (sv)
IT (1) ITTO20010138A1 (sv)
SE (1) SE0100472L (sv)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1290195A2 (en) * 2000-05-15 2003-03-12 Millennium Pharmaceuticals, Inc. 33428, a human metalloprotease family member and uses thereof
NL1022371C2 (nl) * 2003-01-13 2003-11-18 Hoffmann La Roche Nieuwe metallo-proteasen met trombospondine domeinen en daarvoor coderende nucle´nezuur samenstellingen.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451575B1 (en) * 1997-07-25 2002-09-17 Bristol-Myers Squibb Pharma Company Aggrecan degrading metallo proteases
WO2000053774A2 (en) * 1999-03-08 2000-09-14 Neurocrine Biosciences, Inc. Metalloproteinases and methods of use therefor
JP2004507202A (ja) * 1999-03-31 2004-03-11 キュラジェン　コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」
JP2001008687A (ja) * 1999-06-25 2001-01-16 Yamanouchi Pharmaceut Co Ltd 新規金属プロテアーゼ及び該金属プロテアーゼ遺伝子
US6391610B1 (en) * 1999-08-06 2002-05-21 The Cleveland Clinic Foundation Nucleic acids encoding zinc metalloproteases
US6649399B2 (en) * 1999-12-09 2003-11-18 Lexicon Genetics Incorporated Human proteases and polynucleotides encoding the same
EP1136547A3 (en) * 2000-03-22 2002-09-25 Pfizer Products Inc. Adamts polypeptides, nucleic acids encoding them, and uses thereof

Also Published As

Publication number Publication date
DE10107360A1 (de) 2001-09-06
ITTO20010138A0 (it) 2001-02-16
GB2361702A (en) 2001-10-31
JP2001286289A (ja) 2001-10-16
FR2821085A1 (fr) 2002-08-23
AU2303301A (en) 2001-08-23
US20020107361A1 (en) 2002-08-08
GB0103914D0 (en) 2001-04-04
FR2806738A1 (fr) 2001-09-28
SE0100472L (sv) 2001-08-19
ITTO20010138A1 (it) 2002-08-16

Similar Documents

Publication Publication Date Title
Lagares et al. ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis
Kumar et al. Emerging roles of ADAMTSs in angiogenesis and cancer
Kos et al. The current stage of cathepsin B inhibitors as potential anticancer agents
Zou et al. Catalytic activity of human ADAM33
Adrain et al. Mammalian EGF receptor activation by the rhomboid protease RHBDL2
Guinea-Viniegra et al. Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17
Huang et al. In vitro proteolysis of myofibrillar proteins from beef skeletal muscle by caspase-3 and caspase-6
Singh et al. Neuropeptide Y regulates a vascular gateway for hematopoietic stem and progenitor cells
Li et al. Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1
Künnapuu et al. Proteolytic cleavages in the VEGF family: generating diversity among angiogenic VEGFs, essential for the activation of lymphangiogenic VEGFs
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE501268T1 (de) Vorrichtungen und verfahren zur bestimmung von proteaseaktivität
Thorseth et al. Uncovering mediators of collagen degradation in the tumor microenvironment
Salamone et al. Proteolytic enzymes clustered in specialized plasma-membrane domains drive endothelial cells’ migration
BR0310003A (pt) compostos peptìdeos e seu uso como substratos de protease
US20100021450A1 (en) Lys K Endolysin Is Synergistic with Lysostaphin Against MRSA
Leonardi et al. Hemorrhagin VaH4, a covalent heterodimeric P-III metalloproteinase from Vipera ammodytes ammodytes with a potential antitumour activity
Mukai et al. Dysregulation of type II transmembrane serine proteases and ligand-dependent activation of MET in urological cancers
Ropa et al. An expanded role for dipeptidyl peptidase 4 in cell regulation
Fontanil et al. Novel associations within the tumor microenvironment: fibulins meet ADAMTSs
Zupanič et al. Serine pseudoproteases in physiology and disease
SE0100472D0 (sv) Nya metalloproteaser som har trombospondindomäner och nukleinsyrakompositioner som kodar för dessa
BR0113099A (pt) Gene e proteìna relacionados com esquizofrenia
Momota et al. Lamininα3 LG4 module induces keratinocyte migration: involvement of matrix metalloproteinase-9
DE60117998D1 (de) Mutierte furin polypeptide, welche verbesserte eigenschaften aufweisen